Haemophagocytic lymphohistiocytosis, Kawasaki disease and use of intravenous immunoglobulin [1]

Hong Kong Journal of Paediatrics

Volumn 12, Issue 4, 2007, Pages 300-301

  Lee, A C W ^a   Wong, L G ^b  

^a East Shore Hospital   (Singapore)

^b TUEN MUN HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; ETOPOSIDE; IMMUNOGLOBULIN;

DISEASE ASSOCIATION; DISEASE COURSE; DISEASE FREE SURVIVAL; EPSTEIN BARR VIRUS; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HUMAN; LETTER; MONOTHERAPY; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRACTICE GUIDELINE; TREATMENT OUTCOME;

EID: 35649020305     PISSN: 10139923     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (8)

1. Hui WH, Ng DKK, Kwok KL, Lam YY. Haemophagocytic lymphohistiocytosis in an infant: important aspects in management. Hong Kong J Paediatr (New Series) 2007;12:205-11.
2. Chen RL, Lin KH, Lin DT, et al. Immunomodulation treatment for childhood virus-associated haemophagocytic lymphohistiocytosis. Br J Haematol 1995;89:282-90.
3. Chen JS, Lin KH, Lin DT, Chen RL, Jou ST, Su IJ. Longitudinal observation and outcome of nonfamilial childhood haemophagocytic syndrome receiving etoposide-containing regimens. Br J Haematol 1998;103:756-62.
4. Imashuku S, Kuriyama K, Teramura T, et al. Requirement for etoposide in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Clin Oncol 2001;19:2665-73.
5. Anderson D, Ali K, Blanchette V, et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. Transfus Med Rev 2007;21(2 Suppl 1):S9-56.
6. Hemophagocytic Lymphohistiocytosis Study Group. HLH-2004: Treatment protocol of the Second International HLH Study. Stockholm: Histiocytic Society, 2004.
7. Muise A, Tallett SE, Silverman ED. Are children with Kawasaki disease and prolonged fever at risk for macrophage activation syndrome? Pediatrics 2003;112(6 Pt 1):e495.
8. Avcin T, Tse SM, Schneider R, Ngan B, Silverman ED. Macrophage activation syndrome as the presenting manifestation of rheumatic diseases in childhood. J Pediatr 2006;148:683-6.